Prolonged overall survival in gastric cancer patients after adoptive immunotherapy

Table 3 Basic clinical characteristics of patients treated with or without expanded activated autologous lymphocyte adoptive immunotherapy

Characteristic	Patients treated with EAALs (n)	Patients treated without EAALs (n)	P value
Patient number	42	42
Age (yr)
< 60	24	22	0.661
≥ 60	18	20
Sex
Male	34	33	0.786
Female	8	9
Stage
I and II	10	9	0.909
IIIa and IIIb	12	11
IIIc and IV	20	22
Surgery
Yes	33	37	0.242
No	9	5
Radiotherapy
Yes	8	4	0.212
No	34	38
Chemotherapy
≤ 6 cycles	19	24	0.275
> 6 cycles	23	18

EAALs: Expanded activated autologous lymphocytes.